Company Overview
Snapshot
Founded in October 2018 by Rani Cohen, Oded Kraft, and Shai Attia, GrayMatters Health operates with 11–50 employees. The company has raised $18.3 million across four funding rounds from eight investors. In March 2023, the company received an investment from the European Innovation Council (EIC) Fund, with the.
Business overview
GrayMatters Health (GMH) develops digital self-neuromodulation therapeutics designed to help patients regain control over emotion regulation for mental disorders. The company's core product, Prism, is a noninvasive adjunct therapeutic that leverages novel neuroscience-based and brain-mechanism-specific biomarkers. GMH serves the healthcare industry, particularly hospitals and clinics, focusing on mental health and neurology, operating within the Digital Healthcare and Digital Therapeutics sectors.
Strategic signal
In May 2026, GrayMatters Health launched Prism™ Imagine, a generative digital brain biomarker platform. This launch signals the company's continued innovation in mental healthcare, expanding its product portfolio with advanced technology that could enhance personalized treatment approaches and solidify its position as a leader in digital brain biomarkers.
Log in to access full profile ›Company Intelligence Q&A
- What is GrayMatters Health's primary focus?
- GrayMatters Health develops digital self-neuromodulation therapeutics for mental disorders, aiming to help patients regain agency over their emotion regulation.
- What is the Prism product?
- Prism is a noninvasive adjunct therapeutic from GrayMatters Health that utilizes novel neuroscience-based and brain-mechanism-specific biomarkers. Its first product candidate, Prism for post-traumatic stress disorder (PTSD), received FDA clearance in March 2023.
- When did GrayMatters Health receive funding from the European Innovation Council?
- In March 2023, GrayMatters Health received an investment from the.
- What significant product was launched by GrayMatters Health in May 2026?
- In May 2026, GrayMatters Health launched Prism™ Imagine, a generative digital brain biomarker platform designed to support mental healthcare.
- What clinical milestone did GrayMatters Health achieve in February 2026?
- In February 2026, GrayMatters Health reached a clinical milestone of 10,000 Prism PTSD patient sessions, demonstrating significant patient engagement with its digital brain biomarkers.